BioSpace News Archive

Deals

Scinai Immunotherapeutics Regains Compliance with Nasdaq’s Stockholders’ Equity Rule

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI ) today announced today the receipt of formal notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity.

November 20, 2023
·
5 min read
Genetown

QurAlis to Present at the Piper Sandler 35th Annual Healthcare Conference

QurAlis Corporation today announced that Kasper Roet , Ph.D., chief executive officer and founder, will present at the Piper Sandler 35th Annual Healthcare Conference being held November 28-30, 2023 in New York, NY.

November 20, 2023
·
1 min read
Genetown

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

November 20, 2023
·
1 min read
Pharm Country

Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment

Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, announced that it has enrolled one third of its STAR-LLD 1b clinical trial.

November 20, 2023
·
3 min read
Drug Development

Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder

Yamo Pharmaceuticals LLC, a clinical stage pharmaceutical company, announced that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder.

November 20, 2023
·
5 min read
Bio NC

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Basilea Pharmaceutica Ltd announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc.

November 20, 2023
·
3 min read
Biotech Bay

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology Annual Meeting last week.

November 20, 2023
·
3 min read
Drug Development

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

Omnix Medical announced that the U.S. Food and Drug Administration has approved a planned Phase II trial of the Company´s novel anti-infective OMN6.

November 20, 2023
·
3 min read
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Chiesi Farmaceutici S.p.A and Haisco Pharmaceutical Group Co.Ltd announced the execution of a Licensing Agreement to develop, manufacture, and commercialise outside China and adjacent territories HSK31858, a novel, reversible dipeptidyl peptidase 1 inhibitor for respiratory diseases.

November 20, 2023
·
2 min read
Business

Diakonos Oncology Names Ian H. Bellayr, Ph.D. Chief Regulatory Officer

Diakonos Oncology Corporation announced that Ian H. Bellayr, Ph.D., a regulatory expert with the U.S. Food and Drug Administration and National Institutes of Health, has joined the company as its Chief Regulatory Officer.

November 20, 2023
·
3 min read